[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632127":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":197,"collaborators":25,"id":201,"slug":202,"hasResults":203,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":203,"sex":209,"minAge":210,"maxAge":25,"enrollmentInfo":211,"targetDuration":25,"studyType":214,"phases":215,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tocilizumab","EXPERIMENTAL","Endovascular treatment combined with a 240mg tocilizumab injection once",[13],"Drug: Tocilizumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Endovascular treatment combined with placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","240 mg of tocilizumab injection will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"An equivalent volume of placebo will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Xunming Ji","CONTACT","01083198962","jixm@ccmu.edu.cn",{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},"Chuanjie Wu","01083199439","wuchuanjie@ccmu.edu.cn",[40,57,70,82,94,106,119,131,139,151,164,176,188],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Suzhou Municipal Hospital","RECRUITING","Suzhou","Anhui","234000","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.97889,33.63611,{"lat":52,"lon":51},[55],{"name":56,"role":32,"phone":25,"phoneExt":25,"email":25},"Zhengfei Ma",{"facility":58,"status":42,"city":59,"state":60,"zip":61,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Anyang People's Hospital","Anyang","Henan","455000",{"type":49,"coordinates":63},[64,65],114.38278,36.096,{"lat":65,"lon":64},[68],{"name":69,"role":32,"phone":25,"phoneExt":25,"email":25},"Jiangang Zhang",{"facility":71,"status":42,"city":72,"state":60,"zip":73,"country":46,"countryCode":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Nanyang Central Hospital","Nanyang","473000",{"type":49,"coordinates":75},[76,77],112.54659,33.00524,{"lat":77,"lon":76},[80],{"name":81,"role":32,"phone":25,"phoneExt":25,"email":25},"Yifeng Liu",{"facility":83,"status":42,"city":84,"state":60,"zip":85,"country":46,"countryCode":47,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"The First Affiliated Hospital of Henan Medical University","Xinxiang","453000",{"type":49,"coordinates":87},[88,89],113.80151,35.19033,{"lat":89,"lon":88},[92],{"name":93,"role":32,"phone":25,"phoneExt":25,"email":25},"Hongkai Cui",{"facility":95,"status":42,"city":96,"state":60,"zip":97,"country":46,"countryCode":47,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"People's Hospital of Xihua","Zhoukou","466600",{"type":49,"coordinates":99},[100,101],114.63333,33.63333,{"lat":101,"lon":100},[104],{"name":105,"role":32,"phone":25,"phoneExt":25,"email":25},"Chaoqun Li",{"facility":107,"status":42,"city":108,"state":109,"zip":110,"country":46,"countryCode":47,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"People's Hospital of Linyi","Linyi","Shandong","276000",{"type":49,"coordinates":112},[113,114],118.34278,35.06306,{"lat":114,"lon":113},[117],{"name":118,"role":32,"phone":25,"phoneExt":25,"email":25},"Hao Wang",{"facility":120,"status":42,"city":121,"state":109,"zip":122,"country":46,"countryCode":47,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Zibo Central Hospital","Zibo","255000",{"type":49,"coordinates":124},[125,126],118.06333,36.79056,{"lat":126,"lon":125},[129],{"name":130,"role":32,"phone":25,"phoneExt":25,"email":25},"Liangjie Wang",{"facility":132,"status":42,"city":133,"state":134,"zip":135,"country":46,"countryCode":47,"cosmosGeoPoint":25,"geoPoint":25,"contacts":136},"Xianyang First People's Hospital","Xianyang","Shanxi","712000",[137],{"name":138,"role":32,"phone":25,"phoneExt":25,"email":25},"Xingyun Yuan",{"facility":140,"status":42,"city":141,"state":134,"zip":142,"country":46,"countryCode":47,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Yuncheng Central Hospital","Yuncheng","044000",{"type":49,"coordinates":144},[145,146],110.99278,35.02306,{"lat":146,"lon":145},[149],{"name":150,"role":32,"phone":25,"phoneExt":25,"email":25},"Bin Wang",{"facility":152,"status":42,"city":153,"state":154,"zip":155,"country":46,"countryCode":47,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Lishui Central Hospital","Lishui","Zhejiang","323000",{"type":49,"coordinates":157},[158,159],119.91029,28.46042,{"lat":159,"lon":158},[162],{"name":163,"role":32,"phone":25,"phoneExt":25,"email":25},"Xiao Peng",{"facility":165,"status":42,"city":166,"state":154,"zip":167,"country":46,"countryCode":47,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Taizhou enze Hospital","Taizhou","318000",{"type":49,"coordinates":169},[170,171],121.43312,28.66266,{"lat":171,"lon":170},[174],{"name":175,"role":32,"phone":25,"phoneExt":25,"email":25},"Shaoqing Jiang",{"facility":177,"status":42,"city":178,"state":154,"zip":179,"country":46,"countryCode":47,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"People's Hospital of Yueqing","Yueqing","325600",{"type":49,"coordinates":181},[182,183],120.96121,28.11941,{"lat":183,"lon":182},[186],{"name":187,"role":32,"phone":25,"phoneExt":25,"email":25},"Saizhen Wu",{"facility":189,"status":42,"city":190,"state":25,"zip":191,"country":46,"countryCode":47,"cosmosGeoPoint":192,"geoPoint":196,"contacts":25},"Capital Medical Univercity Xuanwu Hospital","Beijing","100053",{"type":49,"coordinates":193},[194,195],116.39723,39.9075,{"lat":195,"lon":194},{"type":198,"investigatorFullName":199,"investigatorTitle":200,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","Professor of Neurology, Capital Medical University Xuanwu Hospital","100632127","phase-3-efficacy-and-safety-of-interleukin-6-receptor-inhibitor-combined-with-endovascular-treatment-in-patients-with-acute-posterior-circulation-large-vessel-occlusion-stroke-100632127",false,"NCT07509645","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3","IRIS-3","Inclusion Criteria:\n\n1. Age 18 years or older, of either sex;\n2. Acute ischemic stroke caused by occlusion of the basilar artery;\n3. Decide to undergo emergency endovascular treatment;\n4. Time from stroke onset to groin puncture within 24 hours;\n5. National Institutes of Health Stroke Scale (NIHSS) ≥ 10;\n6. Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6;\n7. Signed informed consent from the patients or the legally authorized representatives.\n\nExclusion Criteria:\n\n1. Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;\n2. Pre-stroke modified Rankin scale (mRS) score \\>1;\n3. Known allergy to tocilizumab or excipients;\n4. Known allergy to iodinated contrast agents;\n5. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;\n6. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases;\n7. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite blood pressure control;\n8. Neutrophils \\\u003C 2 × 10\\^9 \u002FL;\n9. Platelets \\\u003C 100 × 10\\^9 \u002FL;\n10. Blood glucose \\\u003C2.8 mmol\u002FL (50 mg\u002FdL) or \\>22.2 mmol\u002FL (400 mg\u002FdL);\n11. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\>2 times the upper limit of normal;\n12. Known recent or current serum creatinine \\>2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin;\n13. Pregnant, lactating, or planning pregnancy within 90 days;\n14. Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia;\n15. Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days;\n16. Presence of autoimmune diseases or use of immunosuppressive drugs;\n17. Systemic infectious diseases;\n18. Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study;\n19. Any circumstance that, as assessed by the investigators, might result in harm to the patients if study therapy is initiated;\n20. Other conditions that the investigator considers might affect compliance or preclude participation in this study.","ALL","18 Years",{"count":212,"type":213},348,"ESTIMATED","INTERVENTIONAL",[216],"PHASE3","This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.",[219],"Ischemic Stroke",[221,222,223,224,225],"large vessel occlusion","endovascular treatment","posterior circulation","interleukin-6 inhibitor","neuroprotection","2026-04-29",{"date":228,"type":229},"2026-05-05","ACTUAL",{"date":231,"type":229},"2026-04-22",{"date":233,"type":213},"2027-04-20",{"name":5,"class":6},13]